º¬Ðß²ÝÊÓÆµ

+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

From
From
From
Chronic Kidney Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Chronic Kidney Disease Epidemiology Forecast 2025-2034

  • Report
  • March 2026
  • 150 Pages
  • Global
From
IgA Nephropathy Epidemiology Forecast 2025-2034 - Product Thumbnail Image

IgA Nephropathy Epidemiology Forecast 2025-2034

  • Report
  • March 2026
  • 150 Pages
  • Global
From
Nephrotic Syndrome Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Nephrotic Syndrome Epidemiology Forecast 2025-2034

  • Report
  • March 2026
  • 150 Pages
  • Global
From
From
Renal Anemia Treatment - Global Strategic Business Report - Product Thumbnail Image

Renal Anemia Treatment - Global Strategic Business Report

  • Report
  • August 2026
  • 278 Pages
  • Global
From
Liver Disease Diagnostics - Global Strategic Business Report - Product Thumbnail Image

Liver Disease Diagnostics - Global Strategic Business Report

  • Report
  • August 2026
  • 380 Pages
  • Global
From
From
RG-6299 Sales Forecast and Market Size Analysis - 2034 - Product Thumbnail Image

RG-6299 Sales Forecast and Market Size Analysis - 2034

  • Report
  • May 2026
  • 30 Pages
  • Global
From
Volixibat Sales Forecast, and Market Size Analysis - 2034 - Product Thumbnail Image

Volixibat Sales Forecast, and Market Size Analysis - 2034

  • Report
  • May 2026
  • 30 Pages
  • Global
From
NorUDCA Sales Forecast, and Market Size Analysis - 2034 - Product Thumbnail Image

NorUDCA Sales Forecast, and Market Size Analysis - 2034

  • Report
  • May 2026
  • 30 Pages
  • Global
From
CM-101 Sales Forecast, and Market Size Analysis - 2034 - Product Thumbnail Image

CM-101 Sales Forecast, and Market Size Analysis - 2034

  • Report
  • May 2026
  • 30 Pages
  • Global
From
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2026 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 280 Pages
  • Global
From
Acute Kidney Injury - Pipeline Insight, 2026 - Product Thumbnail Image

Acute Kidney Injury - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 80 Pages
  • Global
From
Acute-on-Chronic Liver Failure (ACLF) - Pipeline Insight, 2026 - Product Thumbnail Image

Acute-on-Chronic Liver Failure (ACLF) - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 60 Pages
  • Global
From
Lupus Nephritis - Pipeline Insight, 2026 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 180 Pages
  • Global
From
Hyperoxaluria - Pipeline Insight, 2026 - Product Thumbnail Image

Hyperoxaluria - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 60 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more